SORT1 and central nervous system cancer: Patient survival data on all glioma and GBM cases revealed that patients with low sortilin had longer survival, with a median survival of 18 months, compared to those with high sortilin, who had median survival of only 12 months (p = 0.0157) (Figure 2G).